Literature DB >> 35759136

Shati/Nat8l Overexpression Improves Cognitive Decline by Upregulating Neuronal Trophic Factor in Alzheimer's Disease Model Mice.

Kakeru Chino1, Naotaka Izuo1, Hiroshi Noike1, Kyosuke Uno1,2, Tomoharu Kuboyama3, Chihiro Tohda4, Shin-Ichi Muramatsu5,6, Atsumi Nitta7.   

Abstract

Alzheimer's disease (AD) is a type of dementia characterized by the deposition of amyloid β, a causative protein of AD, in the brain. Shati/Nat8l, identified as a psychiatric disease related molecule, is a responsive enzyme of N-acetylaspartate (NAA) synthesis. In the hippocampi of AD patients and model mice, the NAA content and Shati/Nat8l expression were reported to be reduced. Having recently clarified the involvement of Shati/Nat8l in cognitive function, we examined the recovery effect of the hippocampal overexpression of Shati/Nat8l in AD model mice (5XFAD). Shati/Nat8l overexpression suppressed cognitive dysfunction without affecting the Aβ burden or number of NeuN-positive neurons. In addition, brain-derived neurotrophic factor mRNA was upregulated by Shati/Nat8l overexpression in 5XFAD mice. These results suggest that Shati/Nat8l overexpression prevents cognitive dysfunction in 5XFAD mice, indicating that Shati/Nat8l could be a therapeutic target for AD.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  AAV vector; Alzheimer’s disease; Amyloid β; BDNF; Cognitive dysfunction; Shati/Nat8l

Mesh:

Substances:

Year:  2022        PMID: 35759136     DOI: 10.1007/s11064-022-03649-2

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   4.414


  45 in total

Review 1.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes.

Authors:  Iryna Benilova; Eric Karran; Bart De Strooper
Journal:  Nat Neurosci       Date:  2012-01-29       Impact factor: 24.884

2.  A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.

Authors:  Thorlakur Jonsson; Jasvinder K Atwal; Stacy Steinberg; Jon Snaedal; Palmi V Jonsson; Sigurbjorn Bjornsson; Hreinn Stefansson; Patrick Sulem; Daniel Gudbjartsson; Janice Maloney; Kwame Hoyte; Amy Gustafson; Yichin Liu; Yanmei Lu; Tushar Bhangale; Robert R Graham; Johanna Huttenlocher; Gyda Bjornsdottir; Ole A Andreassen; Erik G Jönsson; Aarno Palotie; Timothy W Behrens; Olafur T Magnusson; Augustine Kong; Unnur Thorsteinsdottir; Ryan J Watts; Kari Stefansson
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

Review 3.  Structural biology of presenilins and signal peptide peptidases.

Authors:  Taisuke Tomita; Takeshi Iwatsubo
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

4.  Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation.

Authors:  Holly Oakley; Sarah L Cole; Sreemathi Logan; Erika Maus; Pei Shao; Jeffery Craft; Angela Guillozet-Bongaarts; Masuo Ohno; John Disterhoft; Linda Van Eldik; Robert Berry; Robert Vassar
Journal:  J Neurosci       Date:  2006-10-04       Impact factor: 6.167

Review 5.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.

Authors:  Christian Haass; Dennis J Selkoe
Journal:  Nat Rev Mol Cell Biol       Date:  2007-02       Impact factor: 94.444

6.  Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production.

Authors:  M Citron; T Oltersdorf; C Haass; L McConlogue; A Y Hung; P Seubert; C Vigo-Pelfrey; I Lieberburg; D J Selkoe
Journal:  Nature       Date:  1992-12-17       Impact factor: 49.962

7.  Single App knock-in mouse models of Alzheimer's disease.

Authors:  Takashi Saito; Yukio Matsuba; Naomi Mihira; Jiro Takano; Per Nilsson; Shigeyoshi Itohara; Nobuhisa Iwata; Takaomi C Saido
Journal:  Nat Neurosci       Date:  2014-04-13       Impact factor: 24.884

8.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Authors:  Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

9.  A Toxic Conformer of Aβ42 with a Turn at 22-23 is a Novel Therapeutic Target for Alzheimer's Disease.

Authors:  Naotaka Izuo; Chihiro Kasahara; Kazuma Murakami; Toshiaki Kume; Masahiro Maeda; Kazuhiro Irie; Koutaro Yokote; Takahiko Shimizu
Journal:  Sci Rep       Date:  2017-09-18       Impact factor: 4.379

10.  Diosgenin is an exogenous activator of 1,25D₃-MARRS/Pdia3/ERp57 and improves Alzheimer's disease pathologies in 5XFAD mice.

Authors:  Chihiro Tohda; Takuya Urano; Masahito Umezaki; Ilka Nemere; Tomoharu Kuboyama
Journal:  Sci Rep       Date:  2012-07-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.